Morgan Stanley Monopar Therapeutics Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 17, 2024	BUY	$0.31 - $1.35 $248 - $1,080	800 New	800 $0
Q4 2023 Aug 16, 2024	BUY	$0.29 - $0.6 $231 - $480	800 New	800 $0
Q3 2023 Nov 15, 2023	SELL	$0.57 - $1.0 $1,823 - $3,200	-3,200 Reduced 80.0%	800 $0
Q2 2022 Oct 27, 2022	SELL	$1.85 - $2.72 $5 - $8	-3 Reduced 0.07%	4,000 $9,000
Q2 2022 Aug 15, 2022	SELL	$1.85 - $2.72 $5 - $8	-3 Reduced 0.07%	4,000 $9,000
Q1 2022 Oct 27, 2022	BUY	$2.5 - $3.62 $7 - $10	3 Added 0.08%	4,003 $10,000
Q1 2022 May 13, 2022	BUY	$2.5 - $3.62 $5 - $7	2 Added 0.05%	4,003 $10,000
Q4 2021 Feb 14, 2022	BUY	$3.17 - $5.24 $3 - $5	1 Added 0.03%	4,001 $13,000
Q3 2021 Nov 15, 2021	BUY	$4.5 - $6.0 $18,000 - $24,000	4,000 New	4,000 $19,000

Ticker MNPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,725,800
Market Cap $316M
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.